At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 04-24 16:00:00 EDT
0.9400
-0.0364
-3.73%
盘后0.9401
+0.0001+0.01%
19:47 EDT
High1.01Low0.9400Vol171.34K
Open1.01D1 Closing0.9764Amplitude7.17%
Mkt Cap27.52MTradable Cap23.68MTotal Shares29.28M
T/O165.41KT/O Rate0.68%Tradable Shares25.19M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)
TIPRANKS  ·  04-15
Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)
Longeveron Restores Executive Pay After Recent Financing
TIPRANKS  ·  04-11
Longeveron Restores Executive Pay After Recent Financing
BRIEF-Longeveron Inc - Repaid Executives For Compensation Reductions Following Financing - SEC Filing
Reuters  ·  04-11
BRIEF-Longeveron Inc - Repaid Executives For Compensation Reductions Following Financing - SEC Filing
Longeveron Inc - Board Approves 250,000 Rsu Grant to Executives, 500,000 Rsus to CEO - SEC Filing
THOMSON REUTERS  ·  04-11
Longeveron Inc - Board Approves 250,000 Rsu Grant to Executives, 500,000 Rsus to CEO - SEC Filing
Longeveron grants CEO 500,000 RSUs, executives 250,000 after financing closes
Reuters  ·  04-11
Longeveron grants CEO 500,000 RSUs, executives 250,000 after financing closes
BRIEF-Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing
Reuters  ·  04-11
BRIEF-Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing
Longeveron granted Chinese patent for potency assay methods
TIPRANKS  ·  04-08
Longeveron granted Chinese patent for potency assay methods
BUZZ-Longeveron rises as it wins China patent for stem cell test
Reuters  ·  04-08
BUZZ-Longeveron rises as it wins China patent for stem cell test
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (Mscs)
THOMSON REUTERS  ·  04-08
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (Mscs)
Longeveron wins China patent for MSC potency assay methods
Reuters  ·  04-08
Longeveron wins China patent for MSC potency assay methods
Longeveron Receives Extended Nasdaq Compliance Grace Period
TIPRANKS  ·  03-26
Longeveron Receives Extended Nasdaq Compliance Grace Period
Longeveron gains Nasdaq extension; minimum bid compliance deadline moves to September 21, 2026
Reuters  ·  03-26
Longeveron gains Nasdaq extension; minimum bid compliance deadline moves to September 21, 2026
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
TIPRANKS  ·  03-25
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
TIPRANKS  ·  03-19
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
Longeveron Earnings Call: Pivotal Trials, Tight Cash
TIPRANKS  ·  03-19
Longeveron Earnings Call: Pivotal Trials, Tight Cash
Longeveron price target lowered to $2 from $3 at Roth Capital
TIPRANKS  ·  03-19
Longeveron price target lowered to $2 from $3 at Roth Capital
Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate
Benzinga  ·  03-18
Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
GlobeNewswire  ·  03-18
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron FY 2025 net loss widened 41% to USD 22.7 million as revenue fell 50% to USD 1.2 million
Reuters  ·  03-18
Longeveron FY 2025 net loss widened 41% to USD 22.7 million as revenue fell 50% to USD 1.2 million
Longeveron Braces For Q4 Results Following Recent Funding Boost
Benzinga  ·  03-18
Longeveron Braces For Q4 Results Following Recent Funding Boost

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--